Organogenesis Holdings (ORGO)
NASDAQ:ORGO
Top Page
Organogenesis Holdings
(NASDAQ:ORGO)
Select Model
Select Model
Rating:47Neutral
Price Target:
$2.50
▼(-38.73% Downside)
Action:ReiteratedDate:02/27/26
The score is held down primarily by weak cash-flow quality (negative 2025 OCF/FCF) and a materially challenged 2026 outlook from CMS-driven disruption. Technicals also point to bearish momentum (price below key moving averages, negative MACD). Offsetting factors include the 2025 profitability rebound and moderate leverage/liquidity position noted on the earnings call.
Positive Factors
Revenue & margin rebound
A sharp 2025 revenue and profitability rebound demonstrates the company’s ability to scale advanced wound-care sales and convert those sales to strong adjusted EBITDA. Durable commercial execution and higher margins provide operational leverage that can support reinvestment and buffer short-term headwinds.
Negative Factors
Weak cash conversion
Despite GAAP and adjusted profitability in 2025, operating and free cash flow turned negative, signaling poor earnings-to-cash conversion and working-capital strain. Persistent weak cash generation reduces runway, raises refinancing risk, and limits reinvestment capacity if revenue remains pressured.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue & margin rebound
A sharp 2025 revenue and profitability rebound demonstrates the company’s ability to scale advanced wound-care sales and convert those sales to strong adjusted EBITDA. Durable commercial execution and higher margins provide operational leverage that can support reinvestment and buffer short-term headwinds.
Read all positive factors
Organogenesis Holdings (ORGO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$311.31M
Dividend YieldN/A
Average Volume (3M)680.66K
Price to Earnings (P/E)17.7
Beta (1Y)1.62
Revenue Growth2.24%
EPS Growth-67.56%
CountryUS
Employees869
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.31
Shares Outstanding128,640,670
10 Day Avg. Volume591,192
30 Day Avg. Volume680,656
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.51
Price to Sales (P/S)1.16
P/FCF Ratio-26.84
Enterprise Value/Market Cap1.13
Enterprise Value/Revenue0.62
Enterprise Value/Gross Profit0.84
Enterprise Value/Ebitda4.53
Forecast
1Y Price Target
$8.00Price Target Upside96.08% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.17
Revenue Forecast (FY)$401.20M
Organogenesis Holdings Business Overview & Revenue Model
Company Description
Organogenesis Holdings Inc., a regenerative medicine company develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care product...
How the Company Makes Money
Organogenesis makes money primarily by selling its regenerative medicine products used in wound care and surgical applications. Revenue is generated when its products are purchased and used by healthcare providers (e.g., hospitals, outpatient faci...
Organogenesis Holdings Earnings Call Summary
Earnings Call Date:Feb 26, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 07, 2026
Earnings Call Sentiment Negative
The call highlighted an exceptional fourth quarter with record revenue, substantial margin expansion and strong adjusted EBITDA, alongside meaningful commercial and pipeline progress (ReNu, Dermagraft, Smithfield manufacturing). However, sweeping CMS policy changes and specific December CMS commentary have created significant clinician confusion and material utilization disruption that management expects will drive a meaningful revenue decline in 2026 (full-year guidance -25% to -38%, Q1 ~-50%). Rising operating expenses, inventory adjustments and a lower cash balance further accentuate near-term risks. Management is optimistic about market-share recovery in H2 2026, but the near-term outlook is materially challenged.Positive Updates
Record Q4 Revenue Performance
Net product revenue of $225.1M in Q4, up 78% year-over-year and up 50% sequentially; results exceeded the high end of prior guidance ($162M–$187M).
Negative Updates
Material Near-Term Revenue Headwind for 2026
Company expects total net revenue to decline 25% to 38% year-over-year for full-year 2026. Guidance assumes ~50% revenue decline in Q1 2026 and H1 2026 declines ~30%–35% driven by clinician confusion and utilization impact.
Read all updates
Q4-2025 Updates
Positive
Negative
Record Q4 Revenue Performance
Net product revenue of $225.1M in Q4, up 78% year-over-year and up 50% sequentially; results exceeded the high end of prior guidance ($162M–$187M).
Read all positive updates
Company Guidance
Organogenesis guided that total net revenue is expected to decline 25%–38% year‑over‑year for full‑year 2026, with first‑quarter revenue down roughly 50% YoY and first‑half revenue down about 30%–35% YoY due to clinician confusion from late‑2025 CMS commentary; the company expects strong sequential recovery in Q2 and further sequential growth in Q3 and Q4, driving positive adjusted EBITDA in H2 and a high‑teens adjusted EBITDA margin in Q4. The outlook is set against a Q4 2025 base of $225.1 million in net product revenue (up 78% YoY, +50% sequential), Advanced Wound Care of $217.2 million (+83% YoY), Surgical & Sports Medicine $7.9 million (−2% YoY), Q4 adjusted EBITDA of $84.2 million (37% of revenue), GAAP net income of $43.7 million, and year‑end cash of $94.3 million with no debt and a $75 million revolver available.Organogenesis Holdings Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
66
Positive
Cash Flow
38
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 564.17M | 482.04M | 433.14M | 450.89M | 467.36M |
| Gross Profit | 415.06M | 366.30M | 326.66M | 345.87M | 353.16M |
| EBITDA | 83.32M | 15.76M | 36.03M | 40.32M | 87.00M |
| Net Income | 37.03M | 861.00K | 4.95M | 15.53M | 94.20M |
Balance Sheet | |||||
| Total Assets | 598.73M | 497.89M | 460.02M | 449.36M | 443.26M |
| Cash, Cash Equivalents and Short-Term Investments | 93.68M | 135.57M | 104.34M | 102.48M | 113.93M |
| Total Debt | 132.84M | 43.31M | 119.35M | 123.79M | 132.30M |
| Total Liabilities | 164.81M | 112.57M | 181.36M | 183.69M | 201.92M |
| Stockholders Equity | 433.92M | 385.32M | 278.66M | 265.67M | 241.34M |
Cash Flow | |||||
| Free Cash Flow | -24.46M | 4.18M | 6.55M | -9.04M | 30.76M |
| Operating Cash Flow | -10.31M | 14.21M | 30.92M | 24.86M | 61.98M |
| Investing Cash Flow | -14.15M | -10.03M | -24.36M | -33.90M | -31.22M |
| Financing Cash Flow | -17.36M | 27.64M | -5.50M | -2.20M | -1.04M |
Organogenesis Holdings Technical Analysis
Negative
4.08
Price Trends
3.40
Negative
4.24
Negative
4.30
Negative
Market Momentum
-0.32
Negative
24.49
Positive
27.39
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ORGO, the sentiment is Negative. The current price of 4.08 is above the 20-day moving average (MA) of 2.66, above the 50-day MA of 3.40, and below the 200-day MA of 4.30, indicating a bearish trend. The MACD of -0.32 indicates Negative momentum. The RSI at 24.49 is Positive, neither overbought nor oversold. The STOCH value of 27.39 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ORGO.
Organogenesis Holdings Risk Analysis
Organogenesis Holdings disclosed 73 risk factors in its most recent earnings report. Organogenesis Holdings reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Organogenesis Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | $355.36M | 18.78 | ― | ― | -0.85% | -13.50% | |
59 Neutral | $344.74M | -37.26 | -1.44% | ― | 1.76% | 18.31% | |
53 Neutral | $418.31M | 12.57 | 9.59% | ― | -29.91% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $271.30M | -8.30 | 267.84% | ― | 15.10% | 0.18% | |
47 Neutral | $311.31M | 17.73 | 9.56% | ― | 2.24% | -67.56% | |
47 Neutral | $731.91M | -33.91 | 5.62% | ― | 2.83% | 13.61% |
* Healthcare Sector Average
ORGO
Organogenesis Holdings
2.42
-2.08
-46.22%
EBS
Emergent Biosolutions
8.08
3.42
73.39%
SIGA
SIGA Technologies
4.96
-0.06
-1.20%
ESPR
Esperion
2.85
1.35
90.00%
EOLS
Evolus
4.17
-7.88
-65.39%
SNDL
SNDL
1.33
-0.12
-8.28%
Organogenesis Holdings Corporate Events
Executive/Board Changes
Organogenesis Names Patrick McGuire Chief Accounting Officer
Neutral
Feb 23, 2026
On February 18, 2026, Organogenesis Holdings Inc. appointed Patrick McGuire, 40, as Chief Accounting Officer and principal accounting officer, effective immediately, elevating him from his prior role as Vice President, Corporate Controller. McGuir...
Business Operations and StrategyRegulatory Filings and Compliance
Organogenesis Extends Long-Term Leases for Key Facilities
Positive
Dec 29, 2025
On December 22, 2025, Organogenesis Inc. amended its leases for two key facilities at 65 Dan Road and 150 Dan Road in Canton, Massachusetts, extending the terms from their current expiration date of December 31, 2027 to December 31, 2032, with an ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.